RxDoctor Payments Data

Vasumathy Kumaresan, MD

Internal Medicine · Bethlehem, PANPI 1811000631

Payments from drug & device makers

$20,985in general payments, 2019–2025

Across 1,228 payments — averaging $17.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$3K
  • AstraZeneca$2K
  • AbbVie$2K
  • Amgen$2K
  • Pfizer$1K
  • Lilly USA, LLC$1K
  • plus $9K from 54 others

What the payments were for

  • Food & beverage$20,05596%
  • Education$9314%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk160$2,671
AstraZeneca116$2,196
AbbVie(2 entities)129$1,853
Amgen(2 entities)112$1,753
Pfizer107$1,472
Lilly USA, LLC104$1,457
Astellas Pharma US Inc45$1,356
Boehringer Ingelheim59$1,261
Merck47$722
Otsuka America Pharmaceutical, Inc.25$485
Paratek Pharmaceuticals, Inc.22$404
Bayer20$404
Kowa Pharmaceuticals America, Inc.25$381
GSK24$347
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC22$323
Exact Sciences13$292
Lundbeck LLC13$260
Abbott11$235
Bausch Health US, LLC10$234
Johnson & Johnson13$215
Amarin Pharma, Inc.11$200
Sanofi-aventis U.S. LLC11$158
Optinose US, Inc.8$146
Sumitomo Pharma America, Inc.6$141
E.r. Squibb & Sons, L.L.C.9$133
Mannkind Corporation7$126
Novartis7$118
Esperion Therapeutics, Inc.6$112
Takeda Pharmaceuticals U.S.A., Inc.7$108
Biohaven Pharmaceutical Holding Company Ltd.5$94
Antares Pharma, Inc.5$92
Radius Health, Inc.4$87
Madrigal Pharmaceuticals4$86
Axsome Therapeutics, Inc.4$81
Medtronic3$60
Almatica Pharma LLC3$60
Arbor Pharmaceuticals, Inc.4$54
Biohaven Pharmaceuticals, Inc.3$54
Eisai Inc.2$48
Melinta Therapeutics, LLC2$44
Sunovion Pharmaceuticals Inc.2$41
Seqirus USA Inc2$40
Teva Pharmaceuticals USA, Inc.2$39
Corium, LLC2$38
Phadia US Inc.2$37
Philips North America LLC2$36
Cumberland Pharmaceuticals, Inc.2$33
Alnylam Pharmaceuticals Inc.2$31
Scilex Pharmaceuticals Inc.2$30
IBSA Pharma Inc.2$27
Shire North American Group Inc2$27
Supernus Pharmaceuticals, Inc.1$22
Hikma Pharmaceuticals USA1$22
Phathom Pharmaceuticals, Inc.1$21
Genentech USA, Inc.1$20
Impel Pharmaceuticals Inc.1$20
Sanofi Pasteur Inc.1$18
Shield Therapeutics Inc1$18
Vanda Pharmaceuticals Inc.1$17
Tolmar, Inc.1$17

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$20,985 in reported general payments places this provider in the 95th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$235,304
Medicare patients
405
Services billed
2,533

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban260$157,839
JanuviaSitagliptin Phosphate75$56,693
RybelsusSemaglutide45$46,569
MounjaroTirzepatide29$39,185
OzempicSemaglutide35$34,702
FarxigaDapagliflozin Propanediol51$30,427
JardianceEmpagliflozin26$27,782
XareltoRivaroxaban35$23,127
TrulicityDulaglutide13$15,973
MyrbetriqMirabegron34$15,362
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$12,835
Breztri AerosphereBudesonide/Glycopyr/Formoterol13$12,716
Tresiba Flextouch U-200Insulin Degludec12$10,465
EntrestoSacubitril/Valsartan13$8,134
XyostedTestosterone Enanthate11$6,576

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$1,472$157,839260 claims
Novo NordiskRybelsus, Ozempic$2,671$81,27180 claims
MerckJanuvia$722$56,69375 claims
Lilly USA, LLCMounjaro, Trulicity$1,457$55,15842 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$2,196$48,24880 claims
Boehringer IngelheimJardiance, Stiolto Respimat$1,261$33,60438 claims
Johnson & JohnsonXarelto$215$23,12735 claims
GSKTrelegy Ellipta, Breo Ellipta$347$19,27633 claims
Astellas Pharma US IncMyrbetriq$1,356$15,36234 claims
NovartisEntresto$118$8,13413 claims
Antares Pharma, Inc.Xyosted$92$6,57611 claims
Sanofi-aventis U.S. LLCPlavix$158$2,54113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Bethlehem

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →